Labcorp (LH) Partners With Alliance for Clinical Trials to Expand Genetic Testing in Colorectal Cancer Studies

Labcorp Holdings Inc. (NYSE: LH) on May 29, 2026, announced a collaboration with the Alliance for Clinical Trials in Oncology to integrate its genetic testing services into colorectal cancer (CRC) clinical trials. The move aims to advance biomarker-driven research and personalized treatment strategies for one of the most common cancers globally. Under the agreement, Labcorp will provide comprehensive genomic profiling and next-generation sequencing to Alliance-sponsored studies, enabling researchers to better identify patient subgroups, monitor treatment response, and accelerate drug development. The partnership leverages Labcorp's oncology testing infrastructure and the Alliance's extensive clinical trial network. The deal deepens Labcorp's presence in precision oncology, a segment that has seen heightened demand as drugmakers target genetic mutations. The company has been expanding its specialty testing portfolio through partnerships and internal investments, seeking to offset softer COVID-19 testing volumes. Shares of Labcorp have gained 8% year-to-date, supported by growth in its diagnostics and biopharma laboratory services.